Secondly, more comprehensive in vivo and in vitro studies are necessary to elucidate the mechanisms of TUG1 promotes hepatocellular carcinoma immune evasion via upregulating the JAK2/STAT3/PD-L1 signaling pathway. This evidence concerns the gene JAK2 and hepatocellular carcinoma.